Isabelle Nadeau, PhD, CISSN

I am a mom, a Ph.D. scientist and a triathlete. Training is a really big part of my life and I couldn’t image not being active. I’ve raced in road marathons and trail ultra-marathons and completed too many triathlons to count from sprint to full Ironman distance. brings together my passion for helping others achieve their athletic goals and my extensive scientific background.

Before deciding to follow my passion and launch, I worked as a scientist in the field of biochemical engineering for 15 years studying the metabolism of human cells. Working to understand how to effectively feed cells, ultimately led me to want to work with athletes to better understand their nutritional needs. Before launching I sat for the ISSN (International Society of Sports Nutrition) test to become certified as a sports nutritionist and received the second highest score ever achieved on the ISSN test.

The ultimate goal of is to work with athletes and fitness enthusiasts to help them reach their athletic goals. Whether it’s to perform better during a race, be more metabolically efficient or improve their body composition, can help all athletes reach their potential.


1993-2000 MSc and PhD Biochemical Engineering
Biotechnology Research Institute (École Polytechnique of Montréal)

1989-1993 B. Eng. Chemical Engineering
École polytechnique of Montréal

Nutrition Certifications

2016 CISSN, Certified Sports Nutritionist
International Society of Sports Nutrition (

2015-2016 ISSN Diploma in Applied Sports and Exercise Nutrition
Guru Performance Institute (

March 2015-December 2018 METS1, Metabolic Efficiency Training Specialist 1
eNRG Performance Institute (

Refereed Publications

Florence Wu, Kesav Reddy, Isabelle Nadeau, John Gilly, Sara Terpening and David J. Clanton Optimization of a MRC-5 cell culture process for the production of a smallpox vaccine. Cytotechnology, 49, 95-107, 2005.

Nadeau and A. Kamen. Adenovirus production for gene therapy. Review. Biotechnology Advances, 20, 475-489, 2003.

Nadeau, P.A. Gilbert, D. Jacob, M. Perrier, A. Kamen. Low-Protein Medium Affects the 293SF Central Metabolism during Growth and Infection with Adenovirus. Biotechnology and Bioengineering, 77, 91-104, 2002.

Nadeau, D. Jacob, M. Perrier, A. Kamen. 293SF Metabolic Flux Analysis during Cell Growth and Infection with an Adenoviral Vector. Biotechnology Progress, 16, 872-884, 2000.

I.Nadeau, J. Sabatié, M. Koehl, M. Perrier, A. Kamen. Human 293 Cell Metabolism in low Glutamine-Supplied Culture : Interpretation of Metabolic Changes through Metabolic Flux Analysis. Metabolic Engineering 2, 277-292, 2000.

Nadeau, A. Garnier, J. Côté, B. Massie, C. Chavarie, A. Kamen. Improvement of Recombinant Protein Production with the Human Adenovirus/293S Expression System Using Fed-Batch Strategies. Biotechnology and Bioengineering, 51, 613-623, 1996.

Garnier, J. Côté, I. Nadeau, A. Kamen, B. Massie. Scale-up of the Adenovirus Expression System  for  the  Production  of  Recombinant  Protein in Human 293S Cells. Cytotechnology, 15, 145-155, 1994.

Posters and Presentations

Fernandez, J. Femenia, D. Cheung, I. Nadeau, L. Tescione, B. Monroe, J. Michaels and S. Gorfien. Scale-Down Perfusion Process for Recombinant Protein Expression. Cell Culture Engineering X, Whistler, BC, April 14-18, 2006.

Nadeau, N. Pavloff, D. Cheung and J. Michaels. Scalable, Serum-Free-Suspension, Transient Transfection: “It’s in the Bag”. 12th International Biotechnolgy Symposium, Santiago, Chile, October 17-22, 2004.

Reddy, I. Nadeau, G. Seanez, K. Reiter, S. Herrick, F. Wu, M. Coffey. Development of a Scalable Suspension Bioreactor Process for Production of Reovirus (Reolysin). American Society of Gene Therapy, Washington, DC, June 4-8, 2003.

Nadeau, G. Seanez, K. Reiter, F. Wu, J. Gilly. Optimization of a 293 Suspension Process for Adenovirus Production. Cell Culture Engineering VII, Snowmass Village, Colorado, 1-6 April, 2002.

Wu, I. Nadeau, K. Reddy, K. Reiter, S. Kodihalli, J. Gilly, D. Clanton. Development of a MRC-5 Cell Culture Process to Produce Smallpox Vaccine. Cell Culture Engineering VII, Snowmass Village, Colorado, 1-6 April, 2002.

Nadeau, G. Seanez, F. Wu. Evolution from an Adherent Process to a Suspension Process for the Manufacturing of Adenovirus in 293 Cells. Viral Vector and Vaccines, Lake Tahoe, Nevada, 6-9 November, 2001.

Nadeau, G. Seanez, F. Wu. Production of Adenovirus in 293 cells : A Comparative Study between a Suspension and an Adherent Process. 17th ESACT Meeting, Tylosand, Sweden, 12-15 June, 2001.

Nadeau, O. Henry, D. Jacob, M. Perrier, A. Kamen. Enhanced Adenovirus Production by 293 Cells Using a Low-Protein Medium: A Metabolic Flux Analysis. Computer Applications in Biotechnology (CAB8), Quebec city, Canada, June 24 – 27, 2001.

Nadeau, D. Jacob, M. Perrier, A. Kamen.293SF Metabolic flux Analysis during Growth and Infection with an Adenoviral Vector. Cell Culture Engineering Vll, Santa Fe, 5-10 February, 2000.